NCT07417228 The Impact of Concurrent Training on Women Experiencing Symptoms of Menopause
| NCT ID | NCT07417228 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University College Dublin |
| Condition | Menopause Symptoms |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-12-12 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2025-12-12 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to examine the impact of a concurrent training exercise intervention on menopausal symptoms and key physical and mental health outcomes. The proposed study is powered based on a primary outcome of examining the change in menopausal symptoms using the MenQoL questionnaire. Participants (n=70) will be randomised to an intervention or control group. The intervention group will participate in a 12 week online (via zoom) concurrent training programme, consisting of three forty-five minute sessions (on non-consecutive days) per week that align with WHO exercise recommendations for adults and the control group will maintain their regular activity. The exercise classes will be delivered by qualified Sport \& Exercise Scientists and will consist of a combination of bodyweight and resistance band exercises. Each class will consist of a 5 minute warm up, 15 minutes of aerobic exercise, 20 minutes of resistance training, and a 5 minute cool-down. Both groups will engage in pre and post testing through questionnaires (GAD-7, Patient Health Questionnaire-9 (PHQ-9), Menopause-Specific Quality of Life Questionnaire (MENQOL), Body Appreciation (BAS-2)), Pittsburgh Sleep Quality Index Sleep, International physical activity questionnaire (IPAQ), Body image questionnaire (BAS-2) and physical tests (Bod pod, grip-strength, 3-RM leg press, 3-RM cable pull, counter-movement jump and Astrand Rhyming submaximal aerobic test).
Eligibility Criteria
Inclusion Criteria: 1. Women experiencing perimenopause (irregular menstrual cycles of ≥7-day difference in cycle length of consecutive menstrual cycles) and early postmenopause (\< 5 years post menopause). 2. Able to safely engage in a concurrent training interventions that combine both aerobic and resistance training. 3. Must have reliable internet access and a device capable of participating in online training on zoom. 4. Willingness and ability to provide informed consent and comply with study procedures. 5. Aged between 40 and 60 years Exclusion Criteria: 1. BMI \>35 and \<18.5. 2. Currently taking psychotropic medication 3. Has undergone a hysterectomy 4. Current substance abuse 5. Current diagnosis of a mental health disorder 6. Current diagnosis of a chronic illness 7. Currently participating in other structured exercise programmes. 8. Recent surgery or hospitalisation in the past 6 months. 9. Currently taking hormonal contraceptive
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07417228 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 60 Years, studying Menopause Symptoms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07417228 currently recruiting?
Yes, NCT07417228 is actively recruiting participants. Contact the research team at brian.spring@ucd.ie for enrollment information.
Where is the NCT07417228 trial being conducted?
This trial is being conducted at Dublin, Ireland.
Who is sponsoring the NCT07417228 clinical trial?
NCT07417228 is sponsored by University College Dublin. The trial plans to enroll 90 participants.